Cerliponase alfa: Interim Phase I/II data

Interim data from 9 patients ages 3-16 with late-infantile CLN2 disease in an open-label, dose-escalation, international

Read the full 167 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE